Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma

Graeme P. Currie, Daniel K. C. Lee, Kay Haggart, Caroline E. Bates, Brian J. Lipworth

    Research output: Contribution to journalArticlepeer-review

    93 Citations (Scopus)


    We evaluated whether montelukast conferred additive effects in patients with asthma receiving fluticasone/salmeterol (FP/SM) combination and FP alone. Twenty-two patients with mild to moderate asthma completed a double-blind, placebo-controlled study. After a 2-week run-in using FP 250 µg/SM 50 µg 1 puff twice daily, patients entered a randomized crossover period to receive additional montelukast 10 mg daily or placebo for 3 weeks each. For the first 2 weeks, they received FP/SM 1 puff BID, and then they received FP 250 µg 1 puff BID for the 3rd week. The primary outcome was adenosine monophosphate challenge threshold and recovery time; secondary outcomes included surrogate inflammatory markers and lung function. Compared with FP/SM run-in, adding montelukast to FP/SM was better (p < 0.05) than placebo for inflammatory markers but not for lung function. For adenosine monophosphate threshold, recovery, exhaled nitric oxide, and blood eosinophils, there were 1.4 (95% confidence interval, 1.1–1.8) geometric mean fold, 10 minutes (3–17 minutes), 2.1 parts per billion (0.2–3.9 parts per billion), and 88 (34–172) x 106/L differences, respectively. The combination of FP plus montelukast was superior to FP/SM for inflammatory markers but was inferior for lung function. Thus, in patients taking FP/SM or FP, montelukast conferred complimentary effects on surrogate inflammatory markers, which were dissociated from lung function. Further studies are required to evaluate whether these effects of montelukast translate into clinical benefits.
    Original languageEnglish
    Pages (from-to)1232-1238
    Number of pages7
    JournalAmerican Journal of Respiratory and Critical Care Medicine
    Issue number9
    Publication statusPublished - 2003


    • Asthma therapy
    • Leukotriene receptor antagonist
    • Salmeterol
    • Fluticasone


    Dive into the research topics of 'Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma'. Together they form a unique fingerprint.

    Cite this